Department of Urology, National Key Clinical Specialty of Urology, The Second Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin, 300211, China.
Department of Urology, Rugao City People's Hospital, Rugao, Jiangsu Province, China.
Clin Transl Oncol. 2019 Aug;21(8):1067-1075. doi: 10.1007/s12094-018-02029-z. Epub 2019 Jan 12.
Approximately, 30% patients after radical prostatectomy (RP) will undergo post-operative biochemical recurrence (BCR). Present stratification method by TNM staging and Gleason score was not adequate to screen high-risk patients. In this study, we intended to identify a novel set of differentially expressed gene (DEG) signature that can predict BCR after RP.
MATERIALS/PATIENTS: 358 patients after RP with follow-up data were extracted from The Cancer Genome Atlas (TCGA), among which 61 patients had undergone BCR. Key DEGs were confirmed by the intersection of GSE35988 and TCGA_PCa dataset, and their gene expression data were also extracted from TCGA_PCa dataset. Kaplan-Meier plot and Cox proportion hazard regression model were applied to assess the relationship between risk score and survival outcome (BCR).
310 DEGs were confirmed in two prostate cancer dataset. 6 DEGs (SMIM22, NINL, NRG2, TOP2A, REPS2, and TPCN2) were selected to construct a risk score formula. The risk score was a powerful predictive factor independent of TNM stage (HR 3.045, 95% CI 1.655-5.602, p < 0.001).
In this study, a novel 6-gene signature with robust predictive ability on post-operative BCR was constructed and 4 genes (SMIM22, NRG2, NINL and TPCN2) in the 6-gene signature were not reported to be associated with prostate cancer.
大约 30%接受根治性前列腺切除术（RP）的患者将发生术后生化复发（BCR）。目前的 TNM 分期和 Gleason 评分分层方法不足以筛选高危患者。本研究旨在确定一组新的差异表达基因（DEG）特征，以预测 RP 后的 BCR。
材料/患者：从癌症基因组图谱（TCGA）中提取了 358 例接受 RP 且具有随访数据的患者，其中 61 例发生了 BCR。通过 GSE35988 和 TCGA_PCa 数据集的交集确认关键 DEG，并从 TCGA_PCa 数据集提取其基因表达数据。Kaplan-Meier 图和 Cox 比例风险回归模型用于评估风险评分与生存结果（BCR）之间的关系。
在两个前列腺癌数据集中共确认了 310 个 DEG。选择 6 个基因（SMIM22、NINL、NRG2、TOP2A、REPS2 和 TPCN2）构建风险评分公式。风险评分是独立于 TNM 分期的强大预测因素（HR 3.045，95%CI 1.655-5.602，p<0.001）。
本研究构建了一个具有强大预测术后 BCR 能力的新型 6 基因特征，该 6 基因特征中的 4 个基因（SMIM22、NRG2、NINL 和 TPCN2）与前列腺癌无关。
